摘要
目的:探讨黛力新联合信必可治疗支气管哮喘合并焦虑抑郁症的临床观察。方法:收集2016年5月~2017年5月期间在九江学院附属医院门诊接受治疗支气管哮喘且有完整的临床资料和完善的焦虑抑郁量表评分患者60例,按照随机双盲试验分为三组:试验1组、试验2组和对照组,各20例。试验1组在按哮喘规范化治疗吸入信必可基础上加用黛力新口服;试验2组按哮喘规范化治疗吸入信必可;对照组在按哮喘规范化治疗吸入布地奈德气雾剂基础上口服盐酸班布特罗片。比较三组治疗前后抑郁自评量表(SDS)、焦虑自评量表(SAS)哮喘控制测试量表(ACT)评分和第1秒用力呼气容积占预计值百分比(FEV1%pre)及呼气峰流量(PEF)。结果:治疗后第4周和8周,试验1组和试验2组ACT评分、FEV1%pre和PEF均明显较对照组高(P<0.05);试验1组SDS评分和SAS评分均明显较试验2组和对照组低(P<0.05);试验2和对照组在SDS评分和SAS评分未见显著性差异(P>0.05)。结论:黛力新与信必可联合应用治疗支气管哮喘,能有效地改善患者肺功能、支气管哮喘症状和提高患者的生活质量,同时有效地改善患者焦虑抑郁症状。
Objective: To investigate the effect of Deanxit combined with Symbicort clinical observation in the treatment of bronchial asthma complicated with anxiety and depression. Methods: 60 cases bronchial asthma and improve the anxiety and depression From May 2016 to May 2017 in our hospital outpatient were randomly divided into three groups: test group 1, test group 2 and control group, 20 cases in each. The test 1 group was treated with the standardized treatment of asthma Symbicort plus Deanxit oral test; the test 2 group were treated with the standardized treatment of asthma Symbicort; the control group were treated with the standardized treatment of asthma based on oral inhalation of Budesonide Aerosol Bambuterol Hydrochloride Tablets. Self rating Depression Scale(SDS), self rating Anxiety Scale(SAS) and asthma control test scale(ACT) score and FEV_1 percentage of predicted value(FEV_1%pre) and peak expiratory flow(PEF) of three groups before and after treatment were compared. Results: After fourth weeks and 8 weeks after treatment, the PEF scores, FEV_1%pre and ACT in the test 1 group and 2 group were significantly higher than those in the control group(P<0.05). The SDS score and SAS score of the test 1 group were significantly lower than that of the 2 group and the control group(P<0.05). The 2 group and control group in the SDS score and SAS score no significant difference(P>0.05). Conclusions: Deanxit and Symbicort combined treatment of bronchial asthma, can effectively improve the pulmonary function of patients with bronchial asthma, and improve the quality of life of patients, and improve patients with symptoms of anxiety and depression.
出处
《药品评价》
CAS
2018年第1期28-32,共5页
Drug Evaluation
基金
江西省卫生厅科技计划项目(编号:20174019)
关键词
黛力新
信必可
支气管哮喘
焦虑
抑郁
Deanxit
Symbicort
Bronchial Asthma
Anxiety
Depression
作者简介
吴蔚,女,本科,副主任医师,主要从事呼吸内科临床工作.电话：0792-2180100;E-mail：2217800475@qq.com
